CYCN — Cyclerion Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $10.09m
- $6.86m
- $2.00m
- 26
- 32
- 64
- 35
Annual income statement for Cyclerion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.3 | 3.94 | 0.297 | 0 | 2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 83.6 | 55.6 | 18.8 | 13 | 5.26 |
| Operating Profit | -81.3 | -51.6 | -18.5 | -13 | -3.27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -77.8 | -51.6 | -18.2 | -12.6 | -3.06 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -77.8 | -51.6 | -18.2 | -12.6 | -3.06 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -77.8 | -51.6 | -44.1 | -5.26 | -3.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -77.8 | -51.6 | -44.1 | -5.26 | -3.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -52.5 | -27.8 | -8.4 | -3.97 | -1.36 |